Add time:08/19/2019         Source:sciencedirect.com

Four hundred patients completed 4,370 cycles of treatment using Quingestanol (cas 10592-65-1) acetate, 300 mcg daily. Twelve pregnancies occurred resulting in a failure rate of 3.3 per 100 woman years. Seven of these pregnancies were considered drug failures giving a rate of 1.9 per 100 woman years. Cycle length, amount and duration of flow were not significantly different from pretreatment. Intermenstrual bleeding occurred in 51% of the patients and in 12% of cycles; amenorrhea occurred in 20% of the patients and in 5% of cycles. Endometrial biopsies showed normal patterns in 92% of specimens taken during the follioular phase of the menstrual cycle and in 67% of those taken during the luteal phase. An anovulatory pattern was shown in 14% taken during the luteal phase. Numerous laboratory tests demonstrated no abnormalities which could be associated with therapy. The discontinuance rate of 15% for drug-related reasons during the three years of this program indicated favorable patient acceptance. This study indicated that quingestanol acetate used at a daily dose of 300 mcg is a safe and effective oral contraceptive.

We also recommend Trading Suppliers and Manufacturers of Quingestanol (cas 10592-65-1). Pls Click Website Link as below: cas 10592-65-1 suppliers